Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02464163 · ClinicalTrials.gov registry record · Phase 1
Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older
A Phase 1 study, sponsored by Protein Sciences Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 407
- Enrollment target
NCT02464163 is a Phase 1 study that has completed, run by Protein Sciences Corporation. The registered enrollment target is 407 participants.
The verdict
NCT02464163, a Phase 1 study, has completed, sponsored by Protein Sciences Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 407 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and immunogenicity of a recombinant hemagglutinin (rHA) influenza vaccine derived from A/Anhui/1/2013 (H7N9) administered at 3 dose levels in adjuvanted (SE) rHA formulations and 1 dose levels in an unadjuvanted rHA formulation.
Interventions
- BIOLOGICAL Panblok
- BIOLOGICAL rHA adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02464163
The ClinicalTrials.gov registry entry for NCT02464163 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 407 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Protein Sciences Corporation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Panblok is the first listed.
NCT02464163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02464163 about?
NCT02464163 is a clinical study titled "Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older". The purpose of this study is to investigate the safety and immunogenicity of a recombinant hemagglutinin (rHA) influenza vaccine derived from A/Anhui/1/2013 (H7N9) administered at 3 dose levels in adjuvanted (SE) rHA formulations and 1 dose levels in an unadjuvanted rHA formulation.
What is the current status of trial NCT02464163?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 407 participants. The study started on 2015-07. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02464163?
The interventions under investigation include: Panblok (BIOLOGICAL), rHA adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT02464163?
This trial is sponsored by Protein Sciences Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.